Growth hormone releasing hormone (GHRH) signaling modulates intermittent hypoxia-induced oxidative stress and cognitive deficits in mouse

Journal of Neurochemistry

Volumn 127, Issue 4, 2013, Pages 531-540

  Nair, Deepti ^a   Ramesh, Vijay ^a,d   Li, Richard C ^a   Schally, Andrew V ^b,c   Gozal, David ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d NONE   (United States)

Author keywords

8 hydroxydeoxyguanosine; cortex; hippocampus; intermittent hypoxia; malondialdehyde; Morris water maze

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DNA; ERYTHROPOIETIN; GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; HYPOXIA INDUCIBLE FACTOR 1ALPHA; JI 34; MALONALDEHYDE; NEUROPROTECTIVE AGENT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DNA BINDING; FORCED SWIMMING TEST; HIPPOCAMPUS; INTERMITTENT HYPOXIA; LEARNING TEST; LIPID PEROXIDATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; TASK PERFORMANCE; TISSUE LEVEL; UPREGULATION;

MURINAE; MUS; RATTUS;

EID: 84887116540     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12360     Document Type: Article

References (53)

1. Acker T., and, Acker H., (2004) Cellular oxygen sensing need in CNS function: physiological and pathological implications. J. Exp. Biol. 207, 3171-3188.
2. Aviles-Reyes R. X., Angelo M. F., Villarreal A., Rios H., Lazarowski A., and, Ramos A. J., (2010) Intermittent hypoxia during sleep induces reactive gliosis and limited neuronal death in rats: implications for sleep apnea. J. Neurochem. 112, 854-869.
3. Banks W. A., Morley J. E., Farr S. A., Price T. O., Ercal N., Vidaurre I., and, Schally A. V., (2010) Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. Proc. Natl Acad. Sci. USA 107, 22272-22277.
4. Barabutis N., and, Schally A. V., (2008) Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line. Proc. Natl Acad. Sci. USA 105, 20470-20475.
5. Beebe D. W., and, Gozal D., (2002) Obstructive sleep apnea and the prefrontal cortex: towards a comprehensive model linking nocturnal upper airway obstruction to daytime cognitive and behavioral deficits. J. Sleep Res. 11, 1-16.
6. Belaidi E., Joyeux-Faure M., Ribuot C., Launois S. H., Levy P., and, Godin-Ribuot D., (2009) Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J. Am. Coll. Cardiol. 53, 1309-1317.
7. Buchanan G. F., and, Richerson G. B., (2010) Central serotonin neurons are required for arousal to CO2. Proc. Natl Acad. Sci. USA 107, 16354-16359.
8. Calero G., Farre R., Ballester E., Hernandez L., Daniel N., and, Montserrat Canal J. M., (2006) Physiological consequences of prolonged periods of flow limitation in patients with sleep apnea hypopnea syndrome. Respir. Med. 100, 813-817.
9. Dayyat E. A., Zhang S. X., Wang Y., Cheng Z. J., and, Gozal D., (2012) Exogenous erythropoietin administration attenuates intermittent hypoxia-induced cognitive deficits in a murine model of sleep apnea. BMC Neurosci. 13, 77.
10. Dempsey J. A., Veasey S. C., Morgan B. J., and, O'Donnell C. P., (2010) Pathophysiology of sleep apnea. Physiol. Rev. 90, 47-112.
11. Dogrukol-Ak D., Tore F., and, Tuncel N., (2004) Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr. Pharm. Des. 10, 1325-1340.
12. Douglas R. M., Ryu J., Kanaan A., Del Carmen Rivero M., Dugan L. L., Haddad G. G., and, Ali S. S., (2010) Neuronal death during combined intermittent hypoxia/hypercapnia is due to mitochondrial dysfunction. Am. J. Physiol. Cell Physiol. 298, C1594-C1602.
13. Eckeli A. L., Dach F., and, Rodrigues A. L., (2000) Acute treatments with GMP produce antidepressant-like effects in mice. NeuroReport 11, 1839-1843.
14. Freeman R. S., and, Barone M. C., (2005) Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders. Curr. Drug Targets CNS Neurol. Disord. 4, 85-92.
15. Gerlai R., and, Clayton N. S., (1999) Analysing hippocampal function in transgenic mice: an ethological perspective. Trends Neurosci. 22, 47-51.
16. Gozal D., Daniel J. M., and, Dohanich G. P., (2001) Behavioral and anatomical correlates of chronic episodic hypoxia during sleep in the rat. J. Neurosci. 21, 2442-2450.
17. Gozal D., Nair D., and, Goldbart A. D., (2010) Physical activity attenuates intermittent hypoxia-induced spatial learning deficits and oxidative stress. Am. J. Respir. Crit. Care Med. 182, 104-112.
18. Hallschmid M., Wilhelm I., Michel C., Perras B., and, Born J., (2011) A role for central nervous growth hormone-releasing hormone signaling in the consolidation of declarative memories. PLoS ONE 6, e23435.
19. Izdebski J., Pinski J., Horvath J. E., Halmos G., Groot K., and, Schally A. V., (1995) Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc. Natl Acad. Sci. USA 92, 4872-4876.
20. Jackson M. L., Howard M. E., and, Barnes M., (2011) Cognition and daytime functioning in sleep-related breathing disorders. Prog. Brain Res. 190, 53-68.
21. Jaeger L. B., Banks W. A., Varga J. L., and, Schally A. V., (2005) Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc. Natl Acad. Sci. USA 102, 12495-12500.
22. Kaushal N., Ramesh V., and, Gozal D., (2012) Human apolipoprotein E4 targeted replacement in mice reveals increased susceptibility to sleep disruption and intermittent hypoxia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 303, R19-R29.
23. Klukovits A., Schally A. V., Szalontay L., Vidaurre I., Papadia A., Zarandi M., Varga J. L., Block N. L., and, Halmos G., (2012) Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer 118, 670-680.
24. Li R. C., Guo S. Z., Raccurt M., Moudilou E., Morel G., Brittian K. R., and, Gozal D., (2011) Exogenous growth hormone attenuates cognitive deficits induced by intermittent hypoxia in rats. Neuroscience 196, 237-250.
25. Liao F., Taishi P., Churchill L., Urza M. J., and, Krueger J. M., (2010) Localized suppression of cortical growth hormone-releasing hormone receptors state-specifically attenuates electroencephalographic delta waves. J. Neurosci. 30, 4151-4159.
26. Ludwig B., Ziegler C. G., Schally A. V., et al,. (2010) Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc. Natl Acad. Sci. USA 107, 12623-12628.
27. Ludwig B., Rotem A., Schmid J., et al,. (2012) Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc. Natl Acad. Sci. USA 109, 5022-5027.
28. Martin B., Lopez de Maturana R., Brenneman R., Walent T., Mattson M. P., and, Maudsley S., (2005) Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med. 7, 3-36.
29. Morris R., (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47-60.
30. Muccioli G., Ghe C., Ghigo M. C., et al,. (1998) Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. J. Endocrinol. 157, 99-106.
31. Munoz-Moreno L., Arenas M. I., Schally A. V., et al,. (2013) Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer. Int. J. Cancer 132, 755-765.
32. Nair D., Dayyat E. A., Zhang S. X., Wang Y., and, Gozal D., (2011a) Intermittent hypoxia-induced cognitive deficits are mediated by NADPH oxidase activity in a murine model of sleep apnea. PLoS ONE 6, e19847.
33. Nair D., Zhang S. X., Ramesh V., Hakim F., Kaushal N., Wang Y., and, Gozal D., (2011b) Sleep fragmentation induces cognitive deficits via nicotinamide adenine dinucleotide phosphate oxidase-dependent pathways in mouse. Am. J. Respir. Crit. Care Med. 184, 1305-1312.
34. Nanduri J., Yuan G., Kumar G. K., Semenza G. L., and, Prabhakar N. R., (2008) Transcriptional responses to intermittent hypoxia. Respir. Physiol. Neurobiol. 164, 277-281.
35. Obal F. Jr, and, Krueger J. M., (2004) GHRH and sleep. Sleep Med. Rev. 8, 367-377.
36. Polotsky V. Y., Rubin A. E., Balbir A., Dean T., Smith P. L., Schwartz A. R., and, O'Donnell C. P., (2006) Intermittent hypoxia causes REM sleep deficits and decreases EEG delta power in NREM sleep in the C57BL/6J mouse. Sleep Med. 7, 7-16.
37. Row B. W., Liu R., Xu W., Kheirandish L., and, Gozal D., (2003) Intermittent hypoxia is associated with oxidative stress and spatial learning deficits in the rat. Am. J. Respir. Crit. Care Med. 167, 1548-1553.
38. Row B. W., Kheirandish L., Cheng Y., Rowell P. P., and, Gozal D., (2007) Impaired spatial working memory and altered choline acetyltransferase (CHAT) immunoreactivity and nicotinic receptor binding in rats exposed to intermittent hypoxia during sleep. Behav. Brain Res. 177, 308-314.
39. Shan X., Chi L., Ke Y., Luo C., Qian S., Gozal D., and, Liu R., (2007) Manganese superoxide dismutase protects mouse cortical neurons from chronic intermittent hypoxia-mediated oxidative damage. Neurobiol. Dis. 28, 206-215.
40. Szentirmai E., Yasuda T., Taishi P., et al,. (2007) Growth hormone-releasing hormone: cerebral cortical sleep-related EEG actions and expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R922-R930.
41. Szollosi I., Jones M., Morrell M. J., Helfet K., Coats A. J., and, Simonds A. K., (2004) Effect of CO2 inhalation on central sleep apnea and arousals from sleep. Respiration 71, 493-498.
42. Tarasiuk A., Berdugo-Boura N., Troib A., and, Segev Y., (2011) Role of growth hormone-releasing hormone in sleep and growth impairments induced by upper airway obstruction in rats. Eur. Respir. J. 38, 870-877.
43. Telegdy G., and, Schally A. V., (2012a) Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning. Behav. Brain Res. 233, 326-330.
44. Telegdy G., and, Schally A. V., (2012b) Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice. Behav. Brain Res. 233, 232-236.
45. Telegdy G., Tanaka M., and, Schally A. V., (2011) Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice. Behav. Brain Res. 224, 155-158.
46. Thornton P. L., Ingram R. L., and, Sonntag W. E., (2000) Chronic [D-Ala2]-growth hormone-releasing hormone administration attenuates age-related deficits in spatial memory. J. Gerontol. A Biol. Sci. Med. Sci. 55, B106-B112.
47. Vitiello M. V., Moe K. E., Merriam G. R., Mazzoni G., Buchner D. H., and, Schwartz R. S., (2006) Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol. Aging 27, 318-323.
48. Wang T., Hai J., Chen X., Peng H., Zhang H., Li L., and, Zhang Q., (2012) Inhibition of GHRH aggravated acetaminophen-induced acute mice liver injury through GH/IGF-I axis. Endocr. J. 59, 579-587.
49. Wilcox P. G., Pare P. D., Road J. D., and, Fleetham J. A., (1990) Respiratory muscle function during obstructive sleep apnea. Am. Rev. Respir. Dis. 142, 533-539.
50. Xu W., Chi L., Row B. W., et al,. (2004) Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea. Neuroscience 126, 313-323.
51. Yuan G., Nanduri J., Khan S., Semenza G. L., and, Prabhakar N. R., (2008) Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J. Cell. Physiol. 217, 674-685.
52. Yuan G., Khan S. A., Luo W., Nanduri J., Semenza G. L., and, Prabhakar N. R., (2011) Hypoxia-inducible factor 1 mediates increased expression of NADPH oxidase-2 in response to intermittent hypoxia. J. Cell. Physiol. 226, 2925-2933.
53. Zomkowski A. D., Santos A. R., and, Rodrigues A. L., (2005) Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci. Lett. 381, 279-283.